leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 00:49:00 - browse：9

Paul Biondi Flagship

Pharma giant Pfizer is turning to venture firm Flagship for new drug development, signing a deal worth up to $7 billion to mine new medicines from the latter’s portfolio companies.

Flagship and Pfizer announced Tuesday that they will each put $50 million into developing up to 10 drug candidates. Pfizer will have first rights to acquire each for up to $700 million, plus royalties. Flagship’s portfolio companies will also share in any payments that come out of the partnership.

Flagship has historically developed new medicines by forming and spinning out startup companies, some of which have signed their own collaboration deals with the likes of Amgen or Nestlé Health Science. But in recent years, the firm has been pursuing external partnerships through a new business division called Pioneering Medicines, led by former Bristol Myers Squibb executive Paul Biondi. Pioneering Medicines uses technologies and other scientific platforms being developed by Flagship’s portfolio companies to look for possible therapies in disease areas that the startup may not be working in.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Personalized medicine goes far beyond genetics

Wikipedia

WSS

UCB departs biotech trade group BIO

'Null' research findings aren't empty of meaning. Let's publish them

A single drug, study failures leave Anavex with nothing but cash

Burning questions for the 2024 JPM Healthcare Conference

White House finalizes ITC's import ban of latest Apple Watches

The a glaring gap in research on serious mental illness and primary care

hotspot

leisure time

explore

Apple is now the first public company to be valued at $3 trillion

How to ethically and practically extend health care to all

Medical leaders decry Supreme Court decision on affirmative action

Late stage cancers on the rise after pandemic delayed screenings

The high cost of giving birth even with insurance

Late stage cancers on the rise after pandemic delayed screenings

After affirmative action ruling, medical educators look to 'holistic review'

How to ethically and practically extend health care to all

As demand for Covid shots wanes, Moderna seeks its next success

Burning questions for the 2024 JPM Healthcare Conference

leisure time

U.K. sequencing study surfaces new findings about tumor DNA

The biotech scorecard for Q1: 17 stock

Chronically ill young patients struggle to find fertility info

White House finalizes ITC's import ban of latest Apple Watches

Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

JPM: CVS says Medicare Advantage patients are impacting profits

entertainment

Wikipedia

Wikipedia

leisure time